Literature DB >> 18684770

Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature.

Davide Pareyson1, Roberto Fancellu, Caterina Mariotti, Silvia Romano, Andrea Salmaggi, Francesco Carella, Floriano Girotti, Grazietta Gattellaro, Maria Rita Carriero, Laura Farina, Isabella Ceccherini, Mario Savoiardo.   

Abstract

Alexander disease (AD) in its typical form is an infantile lethal leucodystrophy, characterized pathologically by Rosenthal fibre accumulation. Following the identification of glial fibrillary acidic protein (GFAP) gene as the causative gene, cases of adult-onset AD (AOAD) are being described with increasing frequency. AOAD has a different clinical and neuroradiological presentation with respect to early-onset AD, as abnormalities are mainly concentrated in the brainstem-spinal cord junction. We report detailed clinical and genetic data of 11 cases of AOAD, observed over a 4-year period, and a review of the previously reported 25 cases of genetically confirmed AOAD. In our series, onset occurred as late as age 62, and up to 71 in an affected deceased relative. Most cases appeared sporadic, but family history may be misleading. The most frequent symptoms were related to bulbar dysfunction-with dysarthria, dysphagia, dysphonia (seven patients)-, pyramidal involvement (seven patients) and cerebellar ataxia (seven patients). Four patients had palatal myoclonus. Sleep disorders were also observed (four cases). Bulbar symptoms, however, were infrequent at onset and two symptomatic patients had an almost pure pyramidal involvement. Two subjects were asymptomatic. Misdiagnosis at presentation was frequent and MRI was instrumental in suggesting the correct diagnosis by showing, in all cases, mild to severe atrophy of the medulla oblongata extending caudally to the cervical spinal cord. In ten patients, molecular studies revealed six novel missense mutations and three previously reported changes in GFAP. The last typical patient carried no definitely pathogenic mutation, but a missense variant (p.D157N), supposedly a rare polymorphism. Revision of the literature and the present series indicate that the clinical picture is not specific, but AOAD must be considered in patients of any age with lower brainstem signs. When present, palatal myoclonus is strongly suggestive. Pyramidal involvement, cerebellar ataxia and urinary disturbances are common. Less frequent findings include sleep disorders and dysautonomia. Fluctuations may occur. The course is variable, usually slowly progressive and less severe than the AD forms with earlier onset. AOAD is more common than previously thought and might even be the most common form of AD. The diagnosis is strongly suggested by MRI and confirmed by GFAP gene analysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684770     DOI: 10.1093/brain/awn178

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  42 in total

1.  Late onset Alexander's disease presenting as cerebellar ataxia associated with a novel mutation in the GFAP gene.

Authors:  Stephan Schmidt; Mike P Wattjes; Wanda M Gerding; Marjo van der Knaap
Journal:  J Neurol       Date:  2010-12-17       Impact factor: 4.849

Review 2.  The clinical spectrum of late-onset Alexander disease: a systematic literature review.

Authors:  Pietro Balbi; Silvana Salvini; Cira Fundarò; Giuseppe Frazzitta; Roberto Maestri; Dibo Mosah; Carla Uggetti; GianPietro Sechi
Journal:  J Neurol       Date:  2010-08-20       Impact factor: 4.849

3.  Adult Alexander disease with de novo c.1193C>T heterozygous variant in GFAP gene.

Authors:  M Di Giovanni; A Poggiani; S Bianchi; F Rosini; A Rufa; A Federico
Journal:  Neurol Sci       Date:  2015-09-22       Impact factor: 3.307

4.  Unusual presentations and intrafamilial phenotypic variability in infantile onset Alexander disease.

Authors:  Davide Tonduti; Anna Ardissone; Isabella Ceccherini; Giorgio Giaccone; Laura Farina; Isabella Moroni
Journal:  Neurol Sci       Date:  2016-01-07       Impact factor: 3.307

5.  Alexander disease causing mutations in the C-terminal domain of GFAP are deleterious both to assembly and network formation with the potential to both activate caspase 3 and decrease cell viability.

Authors:  Yi-Song Chen; Suh-Ciuan Lim; Mei-Hsuan Chen; Roy A Quinlan; Ming-Der Perng
Journal:  Exp Cell Res       Date:  2011-07-02       Impact factor: 3.905

Review 6.  Sleep apnea in pediatric neurological conditions.

Authors:  Gabor Szuhay; Josh Rotenberg
Journal:  Curr Neurol Neurosci Rep       Date:  2009-03       Impact factor: 5.081

7.  Adult-onset Alexander disease with an R66Q mutation in GFAP presented with severe vocal cord paralysis during sleep.

Authors:  Ayumi Hida; Hiroyuki Ishiura; Noritoshi Arai; Hisayo Fukuoka; Kanehiro Hasuo; Jun Goto; Yoshikazu Uesaka; Shoji Tsuji; Sousuke Takeuchi
Journal:  J Neurol       Date:  2012-05-23       Impact factor: 4.849

8.  Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations.

Authors:  Christina Sundal; Shinsuke Fujioka; Jay A Van Gerpen; Christian Wider; Alexandra M Nicholson; Matt Baker; Elizabeth A Shuster; Jan Aasly; Salvatore Spina; Bernardino Ghetti; Sigrun Roeber; James Garbern; Alex Tselis; Russell H Swerdlow; Bradley B Miller; Anne Borjesson-Hanson; Ryan J Uitti; Owen A Ross; A Jon Stoessl; Rosa Rademakers; Keith A Josephs; Dennis W Dickson; Daniel Broderick; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2013-06-17       Impact factor: 4.891

9.  Identification of a novel nonsense mutation in the rod domain of GFAP that is associated with Alexander disease.

Authors:  Tai-Seung Nam; Jin Hee Kim; Chi-Hsuan Chang; Woong Yoon; Yoon Seok Jung; Sa-Yoon Kang; Boo Ahn Shin; Ming-Der Perng; Seok-Yong Choi; Myeong-Kyu Kim
Journal:  Eur J Hum Genet       Date:  2014-04-23       Impact factor: 4.246

Review 10.  Adult-onset Alexander disease with typical "tadpole" brainstem atrophy and unusual bilateral basal ganglia involvement: a case report and review of the literature.

Authors:  Michito Namekawa; Yoshihisa Takiyama; Junko Honda; Haruo Shimazaki; Kumi Sakoe; Imaharu Nakano
Journal:  BMC Neurol       Date:  2010-04-01       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.